<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Antineoplastic drugs; Antineoplastic drugs: see also Cytotoxic drugs; Cytotoxic drugs; Malignant disease; Cytotoxic drugs: handling guidelines; Cytotoxic drugs: regimens; Cytotoxic drugs: dosage" /><meta name="IX" content="Antineoplastic drugs; Cytotoxic drugs; Malignant disease; Cytotoxic drugs: handling guidelines; Cytotoxic drugs: regimens; Cytotoxic drugs: dosage" /><meta name="IXN" content="Antineoplastic drugs: see also Cytotoxic drugs" /><title>8.1 Cytotoxic drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5180-cytotoxic-drugs.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5180-cytotoxic-drugs.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5180-cytotoxic-drugs.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5179-malignant-disease-and-immunosuppression.htm" title="Previous: 8 Malignant disease and immunosuppression">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5183-side-effects-of-cytotoxic-drugs.htm" title="Next: Side-effects of cytotoxic drugs">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>8.1 </span>Cytotoxic drugs</h1><?highlighter on?><div id="pC" class="jN"><p>The chemotherapy of cancer is complex and should be confined to specialists in oncology. Cytotoxic drugs have both anti-cancer activity and the potential to damage normal tissue; most cytotoxic drugs are teratogenic. Chemotherapy may be given with a curative intent or it may aim to prolong life or to palliate symptoms. In an increasing number of cases chemotherapy may be combined with radiotherapy or surgery or both as either neoadjuvant treatment (initial chemotherapy aimed at shrinking the primary tumour, thereby rendering local therapy less destructive or more effective) or as adjuvant treatment (which follows definitive treatment of the primary disease, when the risk of sub-clinical metastatic disease is known to be high). All cytotoxic drugs cause side-effects and a balance has to be struck between likely benefit and acceptable toxicity.</p><div class="cI" id="PHP5181"><h3>Guidelines for handling cytotoxic drugs</h3><ul><li><p>Trained personnel should reconstitute cytotoxics;</p> </li><li><p>Reconstitution should be carried out in designated pharmacy areas;</p> </li><li><p>Protective clothing (including gloves, gowns, and masks) should be worn;</p> </li><li><p>The eyes should be protected and means of first aid should be specified;</p> </li><li><p>Pregnant staff should avoid exposure to cytotoxic drugs (all females of child-bearing age should be informed of the reproductive hazard);</p> </li><li><p>Use local procedures for dealing with spillages and safe disposal of waste material, including syringes, containers, and absorbent material;</p> </li><li><p>Staff exposure to cytotoxic drugs should be monitored.</p> </li></ul></div><div class="cI"><h3 class="cT">Intrathecal chemotherapy</h3><p>A Health Service Circular (HSC 2008/001) provides guidance on the introduction of safe practice in NHS Trusts where intrathecal chemotherapy is administered; written local guidance covering all aspects of national guidance should be available. Support for training programmes is also available.</p><p>Copies, and further information may be obtained from:</p><p>Department of Health</p><p>PO Box 777</p><p>London SE1 6XH</p><p>Fax: 01623 724524 </p><p>It is also available from the Department of Health website (<a href="http://www.dh.gov.uk/">www.dh.gov.uk</a>)</p></div><p>Combinations of cytotoxic drugs, as continuous or pulsed cycles of treatment, are frequently more toxic than single drugs but have the advantage in certain tumours of enhanced response, reduced development of drug resistance and increased survival. However for some tumours, single-agent chemotherapy remains the treatment of choice.</p><p>Cytotoxic drugs fall into a number of classes, each with characteristic antitumour activity, sites of action, and toxicity. A knowledge of sites of metabolism and excretion is important because impaired drug handling as a result of disease is not uncommon and may result in enhanced toxicity.</p><div><h2>Safe systems for cytotoxic medicines</h2><p>NHS cancer networks have been established across the UK to bring together all stakeholders in all sectors of care, to work collaboratively to plan and deliver high quality cancer services for a given population. NHS cancer networks have websites containing information on local chemotherapy services and treatment (see <a href="http://www.cancer.nhs.uk/networks.htm">www.cancer.nhs.uk/networks.htm</a>). </p><p>Safe system requirements:</p><ul><li><p>cytotoxic drugs for the treatment of cancer should be given as part of a wider pathway of care coordinated by a multidisciplinary team;</p> </li><li><p>cytotoxic drugs should be prescribed, dispensed, and administered only in the context of a written protocol or treatment plan;</p> </li><li><p>injectable cytotoxic drugs should only be dispensed if they are prepared for administration</p> </li><li><p>oral cytotoxic medicines should be dispensed with clear directions for use</p> </li></ul></div><div class="cI"><h3 class="cT">Risks of incorrect dosing of oral anti-cancer medicines</h3><p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p><ul><li><p>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity</p> </li><li><p>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital</p> </li></ul></div><div class="cI" id="PHP5182"><h3 class="cT">Doses</h3><p id="PHP18402">Doses of cytotoxic drugs are determined using a variety of different methods including body-surface area or body-weight. Alternatively, doses may be fixed. Doses may be further adjusted following consideration of a patient's neutrophil count, renal and hepatic function, and history of previous adverse effects to the cytotoxic drug. Doses may also differ depending on whether a drug is used alone or in combination.</p><p>Because of the complexity of dosage regimens in the treatment of malignant disease, dose statements have been omitted from some of the drug entries in this chapter. However, even where dose statements have been provided, detailed specialist literature, individual hospital chemotherapy protocols, or local cancer networks (<a href="http://www.cancer.nhs.uk/networks.htm">www.cancer.nhs.uk/networks.htm</a>) should be consulted before prescribing, dispensing, or administering cytotoxic drugs.</p><p>Prescriptions should <strong>not</strong> be repeated except on the instructions of a specialist.</p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="PHP5183-side-effects-of-cytotoxic-drugs.htm" title="Side-effects of cytotoxic drugs">Side-effects of cytotoxic drugs</a></li><li id="_PHP5199-treatment-for-cytotoxic-induced-side-effects"><a href="PHP5199-treatment-for-cytotoxic-induced-side-effects.htm" title="Treatment for cytotoxic-induced side-effects">Treatment for cytotoxic-induced side-effects</a></li><li id="_PHP5236-alkylating-drugs"><a href="PHP5236-alkylating-drugs.htm" title="8.1.1 Alkylating drugs">8.1.1 Alkylating drugs</a></li><li id="_PHP5282-anthracyclines-and-other-cytotoxic-antibiotics"><a href="PHP5282-anthracyclines-and-other-cytotoxic-antibiotics.htm" title="8.1.2 Anthracyclines and other cytotoxic antibiotics">8.1.2 Anthracyclines and other cytotoxic antibiotics</a></li><li id="_PHP5326-antimetabolites"><a href="PHP5326-antimetabolites.htm" title="8.1.3 Antimetabolites">8.1.3 Antimetabolites</a></li><li id="_PHP5400-vinca-alkaloids-and-etoposide"><a href="PHP5400-vinca-alkaloids-and-etoposide.htm" title="8.1.4 Vinca alkaloids and etoposide">8.1.4 Vinca alkaloids and etoposide</a></li><li id="_PHP5425-other-antineoplastic-drugs"><a href="PHP5425-other-antineoplastic-drugs.htm" title="8.1.5 Other antineoplastic drugs">8.1.5 Other antineoplastic drugs</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5179-malignant-disease-and-immunosuppression.htm">Previous: 8 Malignant disease and immunosuppression</a> | <a class="top" href="PHP5180-cytotoxic-drugs.htm#">Top</a> | <a accesskey="]" href="PHP5183-side-effects-of-cytotoxic-drugs.htm">Next: Side-effects of cytotoxic drugs</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>